Boston-based Cue Biopharma, Inc. (Nasdaq: CUE) announced a USD 50 million private placement to fund clinical development across its immunological disorders pipeline, with the raise arriving roughly ten weeks after a USD 30 million PIPE closed in early May 2026 — signaling continued institutional appetite for the company's autoimmune and allergy strategy.
The transaction is structured as a securities purchase agreement with accredited investors, comprising 1,418,071 shares of common stock at USD 33.21 per share and pre-funded warrants to purchase up to 87,500 shares at USD 33.209 per warrant, with a USD 0.001 exercise price. The placement was led by Cormorant Asset Management, with Columbia Threadneedle Investments among the additional new institutional participants. No placement agent was identified. Cue has agreed to file a resale registration statement covering the shares and warrant shares. Proceeds are directed toward clinical development and general corporate purposes.
The USD 33.21 per-share pricing represents a material step-up from the USD 11.00 effective price in the April 2026 PIPE, reflecting the substantial appreciation in Cue's stock following a series of business development and pipeline events earlier in the year. The prior PIPE had been structured around pre-funded warrants and accompanying warrants, whereas this transaction is predominantly common stock, indicating improved investor terms as the share price rose.
Cue's lead asset is CUE-221 (formerly Ascendant-221, formerly UB-221), a dual-mechanism anti-IgE monoclonal antibody in-licensed from Ascendant Health Sciences in April 2026. The molecule is currently being evaluated in a Phase II study in chronic spontaneous urticaria in China, run by Genesis Life Sciences. Management has indicated that data from this study are expected by the end of Q3 2026. Cue plans to initiate a global Phase IIb trial in food allergy following review of those results. Also in the pipeline is CUE-401, a bifunctional IL-2/TGF-β biologic for autoimmune diseases currently advancing toward an IND filing.